Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WEDERSON MARCOS CLAUDINO

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1588977391
CMS profile
298614
Location
PADUCAH, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$4,210.66

104 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,384.51 95
Travel and Lodging $1,729.02 6
Education $97.13 3

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WEDERSON MARCOS CLAUDINO

NPI 1588977391 · CMS profile ID 298614

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PADUCAH, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588977391?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WEDERSON MARCOS CLAUDINO, NPI 1588977391, CMS profile ID 298614. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588977391?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WEDERSON MARCOS CLAUDINO, NPI 1588977391, CMS profile ID 298614. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588977391?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WEDERSON MARCOS CLAUDINO, NPI 1588977391, CMS profile ID 298614, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1588977391?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

104 matching records · $4,210.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 104 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 104.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $97.7504/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015722205 CMS
Novartis Pharmaceuticals Corporation $34.5604/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991840597 CMS
CTI BioPharma Corp. $13.8204/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039697641 CMS
Gilead Sciences, Inc. $19.2604/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025842787 CMS
Regeneron Healthcare Solutions, Inc. $27.9604/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999127437 CMS
GlaxoSmithKline, LLC. $18.9603/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003174739 CMS
Merck Sharp & Dohme LLC $18.9203/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048608955 CMS
Regeneron Healthcare Solutions, Inc. $14.2003/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999127433 CMS
Celgene Corporation $19.2903/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015714237 CMS
Mirati Therapeutics, Inc. $110.3503/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057988587 CMS
Stemline Therapeutics Inc. $26.7003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040041947 CMS
Mirati Therapeutics, Inc. $21.0003/22/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057988583 CMS
Seagen Inc. $19.4203/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995765253 CMS
GENZYME CORPORATION $19.2603/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050190241 CMS
Amgen Inc. $16.3803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020195099 CMS
Pharmacyclics LLC, An AbbVie Company $14.0903/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998283765 CMS
Merck Sharp & Dohme LLC $710.1703/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646271 CMS
Merck Sharp & Dohme LLC $24.2303/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646275 CMS
Merck Sharp & Dohme LLC $319.0003/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646217 CMS
Merck Sharp & Dohme LLC $40.9903/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646255 CMS
Merck Sharp & Dohme LLC $98.7803/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646263 CMS
Merck Sharp & Dohme LLC $44.7203/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646267 CMS
Merck Sharp & Dohme LLC $48.4403/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646625 CMS
Merck Sharp & Dohme LLC $245.9603/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646221 CMS
Merck Sharp & Dohme LLC $71.2503/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646251 CMS
Merck Sharp & Dohme LLC $319.0003/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048646259 CMS
Merck Sharp & Dohme LLC $63.6403/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048835787 CMS
Rigel Pharmaceuticals, Inc. $12.1903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033400541 CMS
Janssen Biotech, Inc. $74.9903/09/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988342003 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.2503/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000690251 CMS
AstraZeneca Pharmaceuticals LP $19.5103/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014619109 CMS
Mirati Therapeutics, Inc. $14.9803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057988581 CMS
Merck Sharp & Dohme LLC $19.0002/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048608597 CMS
Incyte Corporation $22.3802/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044459205 CMS
PFIZER INC. $10.7602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050641217 CMS
Genentech USA, Inc. $13.5602/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040595978 CMS
Amgen Inc. $13.6902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020195103 CMS
Alexion Pharmaceuticals, Inc. $16.3302/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017022723 CMS
AstraZeneca Pharmaceuticals LP $20.1102/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011280021 CMS
E.R. Squibb & Sons, L.L.C. $18.3502/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015714213 CMS
ADC Therapeutics America, Inc. $15.5402/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053784689 CMS
Incyte Corporation $21.8302/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044459175 CMS
Novartis Pharmaceuticals Corporation $21.9202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991840619 CMS
PFIZER INC. $1.1402/01/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050541601 CMS
PFIZER INC. $12.2902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050568243 CMS
Janssen Biotech, Inc. $18.8701/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988342013 CMS
E.R. Squibb & Sons, L.L.C. $8.5401/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015714177 CMS
E.R. Squibb & Sons, L.L.C. $8.5401/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015714181 CMS
BeiGene USA, Inc. $14.0901/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051177233 CMS
Merck Sharp & Dohme LLC $14.7301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048608593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,230.81 97
PY2020 $3,189.41 82
PY2021 $2,193.36 120
PY2022 $3,554.96 183
PY2023 $4,210.66 104
PY2024 $1,073.06 13
PY2025 $5,044.25 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $236,738.88 7
PY2024 Principal investigator $182,534.02 10
PY2023 Principal investigator $271,300.06 11
PY2022 Principal investigator $82,148.60 6
PY2021 Principal investigator $182,207.67 6
PY2020 Principal investigator $136,673.19 23
PY2019 Principal investigator $227,524.26 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

7 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $18,435.62 12/31/2025 Non-covered Recipient Entity
Mercy Health-Paducah Cancer Center
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926763
Principal investigator 1 Merck Sharp & Dohme LLC $1,223.00 12/31/2025 Non-covered Recipient Entity
Mercy Health-Paducah Medical Oncology and Hematology
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First-line Intervention in Participants with Metastatic Nonsqu No dispute reported 06/30/2026 1232936780
Principal investigator 1 Eli Lilly and Company $131.00 09/09/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC DBA CLINICAL RESEARCH
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187876189
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,406.00 07/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Health, Inc
Phase 3b, Open-label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions No dispute reported 06/30/2026 1235998542
Principal investigator 1 Merck Sharp & Dohme LLC $100,213.00 02/07/2025 Non-covered Recipient Entity
Mercy Health-Paducah Medical Oncology and Hematology
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First-line Intervention in Participants with Metastatic Nonsqu No dispute reported 06/30/2026 1232936778
Principal investigator 1 Eli Lilly and Company $105,830.26 01/08/2025 Non-covered Recipient Entity
BON SECOURS MERCY HEALTH INC DBA CLINICAL RESEARCH
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187876187
Principal investigator 1 Merck Sharp & Dohme LLC $4,500.00 01/03/2025 Non-covered Recipient Entity
Mercy Health-Paducah Cancer Center
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib monotherapy in participants with r No dispute reported 06/30/2026 1232917485